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Targeting the glial-derived neurotrophic factor (GDNF) and related 
molecules for controlling normal and pathologic pain 
Adalberto Merighi 
 
Introduction: GDNF and its family of ligands (GFLs) have several functions in the nervous system. 
As a survival factor for dopaminergic neurons, GDNF was used in clinical trials for Parkinson’s 
disease. However, GFLs their receptors are potential targets for new pain-controlling drugs. Such a 
potential should not be underestimated because molecules with analgesic activities in rodents 
mostly failed to be effective in translational studies. 
Areas covered: The circuitry, molecular and cellular mechanisms by which GFLs control 
nociception, their intervention in inflammatory and neuropathic pain, the problems related to 
effective GDNF delivery to the brain, the possibility to target the GFL receptor complex rather than 
its ligands, also by the use of non-peptidyl agonists, are discussed.  
Expert opinion: In nociceptive pathways, an ideal drug should either: i. Target the release of 
endogenous GFLs from large dense-cored vesicles (LGVs) by acting e.g. onto the 
phosphatidylinositol-3-phosphate [PtdIns(3)P] pool, which is sensitive to Ca
2+ modulation; ii. Target 
the GFL receptor complex. Besides to XIB403, a thiol molecule that enhances GFRα family 
receptor signaling, existing drugs such as retinoic acid and amitriptyline should be considered for 
effective targeting of GDNF, at least in neuropathic pain. The approach of pain modeling in 
experimental animals is discussed. 
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1. Introduction 
Chronic pain is a major clinical and economic issue, and several cross-sectional studies indicate that 
it affects up to 25-30% of the total adult population worldwide.  Under this umbrella term are 
comprised several different types of long-lasting pain, including inflammatory pain (e.g. in 
arthritis), cancer pain, and neuropathic pain that follows to injury (e.g. an ischemic insult or a 
trauma) of the peripheral and/or central nervous system. The term is somewhat ambiguous, as its 
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current use implies the absence of a stimulus-to-pain correlation, i.e. a persistence of pain that 
outlasts its causative event. This always occurs in neuropathic pain and, sometimes but not always, 
also in inflammatory pain. Whereas the protective role of nociceptive pain appears obvious, 
inflammatory and neuropathic pain persisting after their causative event(s) is(are) ceased are a 
maladaptive response of the nociceptive system, and must be regarded as fully pathologic 
conditions. Hyperalgesia and allodynia typically characterize all types of chronic pain, whereas 
burning, paresthesia and dysesthesia are additionally present in neuropathic pain.  
It is now widely accepted that an altered plasticity of the nociceptive system is responsible for the 
onset of chronic pain, resulting from peripheral and central sensitization of the nociceptors, the 
primary sensory neurons involved in the processing of pain-related stimuli [1]. In their simplest 
configuration, somatic and visceral pain pathways are made of a polyneuronal chain, having a 
nociceptor at its beginning, converging nociceptive information to the thalamus, and, from there, to 
the cerebral cortex (Figure 1). An important feature of the nociceptive system is that its responses to 
noxious stimuli (i.e. the actual or potential tissue damaging events) can be modulated by local 
circuit interneurons that, in normal conditions, calibrate the system response to the stimulus 
intensity and duration in time. One important site for this modulatory action is the substantia 
gelatinosa (lamina II) of the spinal cord and the spinal nucleus of the trigeminal nerve (SNuT). The 
nociceptors thresholds are lower than the stimulus intensity needed to damage tissues (i.e. they exert 
what is called a warning function), and, once activated, they release a cocktail of fast-acting 
(glutamate)  and slow acting neurotransmitters (peptides, trophic factors) from their central 
terminals in the spinal cord and SNuT.  
In nociceptive pain, only the nociceptors are activated, their response is short-lasting; pain has a 
high threshold, and, thus, plays its physiological protective function. In inflammatory pain, also 
non-nociceptive primary sensory neurons come into play, the system displays a long-lasting 
response (central sensitization), pain has a low threshold, and plays an important function in the 
repair process.  Although acute inflammation produces a transient central sensitization that is 
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beneficial for tissue healing, chronic inflammatory pain is associated with a long-lasting and, 
sometimes, permanent central sensitization that persists after inflammation has ceased. Similarly, in 
neuropathic pain the nociceptive system becomes permanently sensitized, also as a consequence of 
neuronal damage, ectopic neuronal firing and microglia activation.  
There are at present no satisfactory treatments for chronic pain as the medications of choice in 
clinical settings, such as non-steroidal anti-inflammatory drugs and opioids, are often inadequate 
and linked to undesirable side-effects. In addition, molecules with analgesic activities in rodents, up 
to now, unfortunately failed to be effective in translational studies, despite the urgent need for 
effective treatments in pathologic pain patients. 
The glial-derived neurotrophic factor (GDNF) [2] is the first discovered member of a group of 
closely related neurotrophic factors that are collectively referred to as the GDNF family ligands 
(GFLs). Although the interest for the use GFLs in therapy was initially focused on 
neurodegeneration [3], artemin (ARTN), one of the GFLs, was long ago the first growth factor to be 
demonstrated to successfully reverse and normalize neuropathic pain in rats [4].  
Here, I will discuss current experimental evidence and rationale for the development and use of 
GDNF, ARTN and their receptor complex ligands as new pain-controlling drugs. 
2. GFLs and their receptors 
All the four GFLs, i.e. GDNF, neurturin (NRTN), ARTN and persephin (PSPN) display potent 
neurotrophic activity and promote the survival of several different populations of central and 
peripheral neurons [5].  GFLs signal through a unique receptor complex that consists of a common 
receptor and a ligand-specific co-receptor [6]. The common receptor is the transmembrane receptor 
tyrosine kinase (RTK) rearranged during transfection (RET) that has a typical intracellular kinase 
domain and activates multiple cellular signaling pathways [7]. The ligand-specific co-receptor is a 
cell surface-bound GDNF family receptor α (GFRα) that binds (but not exclusively) one of the 
GFLs [3, 5]. Thus, GDNF preferentially binds to GFRα1, NRTN to GFRα2, ARTN to GFRα3, and 
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PSPN to GFRα4. However, GDNF can also bind to GFRα2 and GFRα3, but with lower affinity, 
and still activates RET, although it remains to be established whether this signaling is 
physiologically relevant in vivo. All GFRα receptors are anchored to the cell plasma membrane 
through a glycosyl phosphatidylinositol (GPI) link [8]. GFLs are also able to signal in a RET-
independent way and, among others, utilize the neural cell adhesion molecule (NCAM) as an 
alternative signaling receptor [9]. 
3. GFLs and the control of nociception 
GFLs, like other neurotrophic factors, display pleiotropic functions that may be different during 
development, adulthood and in response to disease or injury. In addition, the nociceptive system is 
capable of remarkable plasticity. Thus, the definition of the role of GFLs in the normal processing 
of pain has been and still remains a complicated issue. In the following, I will mainly discuss the 
available data in the spinal nociceptive system, as it has been the most widely investigated part of 
the entire somatosensory system in relation to the intervention of GFLs in pain processing. 
3.1  Localization studies 
Of the GFL receptor complex ligands, only GDNF was detected in nociceptors although the three 
GFRα isoforms and RET have all been localized to dorsal root ganglia (DRGs).  
Initial studies suggested that GDNF was expressed in small- to medium-sized DRG neurons and in 
fibers of laminae I–II of the spinal dorsal horn (SDH), likely after having been anterogradely 
transported along the central projections of these neurons [10]. Recently it was demonstrated that 
GDNF is normally expressed by a specific subpopulation of peptidergic calcitonin gene-related 
peptide (CGRP)/somatostatin 28 (SST28)-immunoreactive (IR) murine nociceptors and by their 
central terminals at type Ib glomeruli in SDH lamina II [11]. These neurons and their terminals were 
also decorated by the isolectin B4 (IB4) produced by the plant Griffonia simplicifolia [12], a marker 
of the cell membrane of the DRG neurons supported by GDNF during development [13].  Very 
likely, a similar pattern occurs in rat considering the mirroring distribution of brain-derived 
6 
 
neurotrophic factor (BDNF)/tyrosine kinase receptor B (TrkB) and GDNF in the two species  [14, 
15].  
The GFL receptor complex components have been detected in rat [16-22] and mouse [11] DRGs 
and spinal cord. In rat, about half of unmyelinated IB4+ nociceptive C-fibers express GFRα1, and 
nearly 80% of the IB4+ nociceptors express either GFRα1 or GFRα2. Light microscopy studies 
showed that GFRα1 is mainly expressed in lamina IIo and GFRα2 in lamina IIi of the lumbar [21] 
and sacral spinal cord [17]. Notably, GFRα2-KO mice showed a normal acute pain response in the 
formalin test but a markedly attenuated persistent phase, indicating a deficit in the inflammatory 
pain response [23].  GFRα3 appeared to be mainly (if not exclusively) present in nociceptive 
peptidergic (CGRP+) DRG neurons and their peripheral unmyelinated C-fibers [24, 25]. These 
neurons were also reported to express RET and the transient potential vanilloid receptor type 1 
(TRPV1) [26]. In mouse, the GFRα1/RET receptor complex was localized in non-peptidergic 
nociceptors and their terminals in SDH and, ultrastructurally, at type Ia glomeruli (Figure 2) [11].  
Similarly to rodents, adult human DRG neurons express RET and the three GFRα isoforms. GFRα1 
and RET were detected in both large and small sized cells. In the adult spinal cord, mRNAs were 
found encoding for GFRα1 and RET, but, notably, the GFRα2 mRNA was only detected in 
embryos [27]. RET was also localized to the human trigeminal ganglion [28]. 
Interspecies comparisons are difficult because the majority of rat work was focused on the 
survival/neuroprotective effect of the GDNF and to ascertain the plastic response of the sensory 
system to different types of injury, rather than considering a putative intervention as a pain 
modulator. The concurrent localization of GFRα1 and GFRα2 in DRGs is an important issue, since 
the latter also binds GDNF in vitro  [5], thus leaving the possibility open for GDNF to act also on 
GFRα2-expressing neurons. However, it seems highly questionable that GDNF interacts in 
vivo with ligands other than GFRα1 [29], and it should be recalled that specific types of low-
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threshold mechanoreceptors but not the nociceptors were identified by a unique co-expression 
pattern of RET and GFRα2 [30].  
3.2  Functional studies 
The concurrent presence of GDNF and its receptor complex after in situ analysis in adult rodents 
and humans is supportive for a modulatory role of GDNF in the somatosensory system. Therefore, 
while the intervention of GDNF in the maturation and maintenance of subsets of primary sensory 
neurons is well established [12, 13],  today we begin to understand that it also modulates their 
functional properties once maturity is reached. After the initial suggestion that GDNF undergoes 
anterograde transport along primary afferent fibers projecting to periphery and spinal cord [10, 31], 
evidence was provided that GDNF can be actively secreted [32]. Initial cues on the modulatory role 
of GDNF in somatosensory system derived from the demonstration of its capability to enhance 
SOM expression [33] and release from DRGs in vivo [33-35], and capsaicin-stimulated release of 
CGRP from cultured DRG neurons [36]. The hypothesis that GDNF was as a modulator of the 
nociceptive information transfer between first- and second-order neurons in SDH was thus put 
forward [35], but still it remained controversial [25, 37] as both pro- and anti-nociceptive effects 
were reported, depending on the peripheral territory innervated (skin, muscle), type of pain 
(inflammatory, neuropathic), and stimulus (mechanical, thermal, noxious) – see 4. GFLs and 
pathological pain. 
Recently, this issue has been clarified in a mouse slice preparation [11]. In this context, capsaicin 
was capable to release GDNF from peptidergic CGRP/SST28-IR nociceptors, and GDNF was shown 
to exert a tonic inhibitory control on the glutamate excitatory drive of SDH neurons after ERK1/2 
phosphorylation assay, real-time Ca2+ imaging and patch-clamp experiments. The reduction of the 
capsaicin-evoked [Ca2+]i rise and of the frequency of miniature excitatory postsynaptic currents 
(mEPSCs) in SDH neurons was specifically abolished after ablation of GFRα1 by enzymatically 
cutting its membrane GPI anchor [8] . In the same work, the selective localization of GDNF  in 
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large dense-cored vesicles  (LGVs) was also demonstrated. These observations led to conclude that 
GDNF released from peptidergic CGRP/ SST28-IR nociceptors acutely depressed neuronal 
transmission in SDH signaling to non-peptidergic IB4+ nociceptors at glomeruli that either display 
GDNF/SST28 (type Ib)-IR or GFRα1/IB4 labeling (type Ia). These data are of potential 
pharmacological interest as they highlight a novel modality of cross talk between nociceptors that 
may be relevant for discrimination of pain modalities (Figure 2) and strengthened the idea that 
GDNF could enter the scene as a potential therapeutic target in the control of pain. 
4. GFLs and pathological pain 
4.1. Animal studies 
Animal studies aiming to elucidate the role of GFLs in pathological pain have been carried out in 
rats and mice and were, for the most, focused onto GDNF. They substantially converged to 
demonstrate that GDNF has different effects in inflammatory and neuropathic pain, and that 
hyperalgesic effects (Table 1) are seen in the peripheral nervous system, whereas analgesic effects 
(Table 2) occur in central neurons. Only limited data are available for ARTN and even less for 
NRTN. Several discrepancies can be found when comparing these studies.  At least some of these 
discrepancies can be related to the use of animals not only of different species, but also strains and 
sexes, as substantial differences under these respects were observed e.g. in the anti-depressive 
response to ketamine an NMDA receptor antagonist widely employed in the control of pain [38]. 
4.1.1. ARTN 
Anti-ARTN antibodies have been reported to partly revert the inflammatory pain that follows a 
local injection of complete Freund’s adjuvant (CFA) in rat [39]. Mice overexpressing ARTN in 
keratinocytes displayed an increased sensitivity to several types of pain-inducing stimuli, and the 
intraplantar injection of ARTN in wild-type controls resulted in transient thermal hyperalgesia [40].  
Anti-ARTN antibodies in rats and mice were instead inefficacious in blocking neuropathic pain that 
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followed spinal nerve ligation (SNL) [39], in keeping with the observation that subcutaneous ARTN 
blocked the mechanical and thermal hyperalgesia in the same experimental paradigm in rats [4].  
In brief, these observations converge to indicate that ARTN is pronociceptive at periphery in 
inflammatory pain and antinociceptive in spinal cord under neuropathic conditions.   
4.1.2. GDNF 
4.1.2.1. Inflammatory pain 
When inflammatory pain was elicited after challenge of cutaneous, muscular or articular afferents a 
tissue-specific response to GDNF was observed (Table 1).  
Cutaneous afferents have been challenged with direct intraplantar/intradermal injections of GDNF 
or CFA. Intraplantar injection of GDNF induced thermal [41] or mechanical hyperalgesia, the 
underlying mechanism being primarily associated with IB4+ and GFRα1 expressing nociceptors 
[42-44]. However, CFA-induced mechanical and thermal hyperalgesia were reversed or blocked by 
GDNF in another study [45]. Besides to behavioral effects, CFA upregulated the GDNF 
protein/mRNA content of DRGs. Notably, after surgical plantar incision, mechanical and thermal 
hyperalgesia were associated with a downregulation of the GDNF mRNA in skin [46].  
The inflammatory response to locally administered GDNF in the first set of studies was 
substantially inferred after behavioral responses, and it cannot be excluded that the proalgesic 
effects of GDNF were indirect and linked e.g. to an overproduction of interleukin-18 (IL18) at the 
injection site. Notably, IL18 is a known mediator of pain [47] and can be upregulated by GDNF in 
skin [48] . Thus, the physiological relevance of this type of experimental paradigm can be 
questioned. Interpretation is further complicated by the possibility that deeper tissues and not the 
skin are involved in GDNF-induced edema, therefore being responsible of the inflammatory 
behavior [49] . On the other hand the studies implying an anti-nociceptive effect of GDNF in 
cutaneous inflammatory pain are in line with the functional observations in a slice model of 
inflammation [11]. 
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Mechanical hyperalgesia was observed in several studies where GDNF was injected 
intramuscularly [50-52], its cellular/molecular substrates being associated with IB4+ and GFRα1-IR 
nociceptors [50]. Another study has shown that anti-GDNF antibodies blocked the mechanical 
hyperalgesia induced by muscle lengthening contraction, the underlying mechanism involving a 
cyclooxygenase-2 (COX2)-dependent upregulation of the GDNF mRNA [53].  
Anti-GNDF antibodies also reduced the delayed thermal hyperalgesia that followed CFA 
intraarticular injection [54]. Finally, a proalgesic role for GDNF was also inferred in a very recent 
study where inflammatory pain was induced after experimental bone carcinogenesis [55]. 
In brief, it therefore appears that deep-tissues’ inflammatory pain is positively regulated by GDNF, 
whereas the picture for cutaneous pain is much less well defined. 
4.1.2.2. Neuropathic pain 
GDNF was clearly antinociceptive in neuropathic pain (Table 2). All studies employing the classic 
experimental paradigms to induce this type of pain converged to demonstrate that GDNF was 
capable to block heat/mechanical hyperalgesia and allodynia. In these experiments the growth 
factor was mainly administered intrathecally [56-60] or intraspinally [61, 62], but also directly into 
the DRGs [62, 63], in contact with the lesioned nerve [56], or intramuscularly [64]. It is worth 
nothing that allodynia and thermal hyperalgesia were also blocked after direct injection of GDNF 
into the locus coeruleus [65], i.e. targeting the descending pain inhibitory system. Relevant to the 
present discussion, not only the intact molecule was employed [56-60, 65], but GDNF was also 
delivered with different types of viral vectors [61-64] or using a slowly releasing chitosan matrix 
[56]. Finally, an antinociceptive action for GDNF was proposed in a study on induced herpetic 
neuralgia [66]. 
4.1.3. NRTN 
NRTN was used in parallel to ARTN and GDNF in a mouse study where inflammatory pain was 
induced by CFA, or the GFLs were locally administered by intraplantar injections [41]. As a 
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decrease of expression was observed after CFA, it can be tentatively hypothesized that NRTN was 
antinociceptive in this type of pain. 
4.2. Human studies 
Although limited in numbers, human studies appear to confirm pre-clinical animal data. Initial 
observations on the presence of growth factors in patients suffering from interstitial cystitis or 
bladder cancer demonstrated, among others, an increase of urinary GDNF [67]. More recently [68],  
urinary GDNF was shown to decrease in response to treatment of refractory bladder pain with the 
analgesic onabotulinum toxin A (OnabotA), although its basal levels in patients were not 
significantly different from those in normal subjects. The decrease in urinary GDNF after OnabotA 
indicated a local process of release, thus suggesting that GDNF could have a role in visceral pain in 
general, and in urinary bladder pain in particular. Observations in bladder pathologies thus appear in 
line with the notion that GDNF intervenes as a pronociceptive factor in peripheral inflammatory 
pain of deep tissues’ afferents. In the search of useful biomarkers for pain conditions, GDNF and 
related molecules were also investigated in cerebro-spinal fluid (CSF) and blood. In patients 
suffering from chronic migraine or fibromyalgia, the CSF content of GDNF and SOM were reduced 
[69]. In a subsequent study in long-term pain patients, however, GDNF resulted to be increased in 
CSF but decreased in blood, implying  that changes of the GDNF levels in CNS are not traceable 
peripherally under chronic pain conditions  [70]. To explain their results, authors have hypothesized 
that a major component of blood GDNF comes from sources other than CNS, as GDNF does not 
cross the blood brain barrier (BBB).  Finally, in another recent preliminary report the CSF levels of 
GDNF were seen to be higher in patients suffering from neuropathic pain when compared with 
those of patients suffering from arthritic back pain [71].  These observations are more difficult to be 
grouped in a coherent frame encompassing a clear relationship of GDNF and pain. In other studies 
such a relationship was even lacking. Patients suffering from painful and non-painful necrotic 
vasculitic neuropathies had increased levels of GDNF and GFRα1 mRNAs in sural nerve biopsies, 
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but values of both mRNAs were not significantly different in relation to the presence or absence of 
pain [72]. Similarly, in a study on the course of UV-induced skin inflammatory hyperalgesia, RT-
PCR analysis revealed an up-regulation of the ARTN but not GDNF, GFRα1, or GFRα3 mRNAs 
[73]. 
Under this context, ARTN  (BG00010) was very recently employed in the first-in-human, double-
blind, placebo-controlled, randomized, dose-escalation study on subjects with unilateral sciatica: 
after enrolment of forty-eight  subjects, BG00010 was generally well tolerated, but, at present,  not 
yet associated with any clear, dose-dependent trends in Likert pain scores [74]. 
5. Delivery of GFLs to the brain  
Much of what we know about delivery of GFLs to the brain comes from pre-clinical and clinical 
studies on Parkinson’s disease (PD) or other neurodegenerative conditions, see e.g. [3].  
However, it is worth noting here that the goal of GFL-based therapies in neurodegenerative diseases 
is to exploit the growth factor activity of the molecules, whereas in the case of effective pain-
controlling drugs is the modulatory activity to be targeted.  
5.1. Protein based-therapy  
Bioavailability is, in general terms, surely one of the most important issues in protein-based 
therapies [75]. GDNF is a large basic protein of 134 amino acids of 15 kDa and cannot be 
transported across the BBB. Consequently, the direct delivery of GDNF to the brain was the 
primary focus of translational research. Delivery strategies have included the direct administration 
of the molecule, its encapsulation in microspheres composed of biodegradable polymers to achieve 
a controlled release over a prolonged period of time, DNA nanoparticle gene transfer, and 
convection-enhanced delivery [76-79]. Interactions of GDNF with components of the extracellular 
matrix ,its activation of receptors other than RET/GFRα1, induction of anti-GDNF antibodies by 
recombinant GDNF are all factors hampering the use of the full molecule in therapy. Interestingly, 
it was demonstrated that insect cell-derived GDNF:tetanus toxin C retains its bi-functional activity 
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in mammalian CNS in vivo and improved the delivery of GDNF to spinal cord following 
intramuscular- or intrathecal administration [80]. 
5.2 GFL mimetics and small molecules targeting the GFLs’ receptors 
The term neurotrophic mimetics is used to indicate small molecule agonists of the neurotrophic 
factors. Being of small size, these molecules should have the advantage of crossing the BBB and 
should not induce anti-antibodies production. Whereas several mimetics exist for nerve growth 
factor (NGF) or BDNF, gliafin is the only GDNF mimetic available today. Gliafin (153-
ETMYDKILKNLSRSR-167; UniProtKB entry no. Q07731) is a small peptide that displays GDNF-
like activity and was recently demonstrated to induce efficient differentiation and functional 
integration of transplanted stem cell derivatives [81]. It has not been tested yet as an alternative to 
GDNF in local delivery experimental paradigms of inflammatory or neuropathic pain, but it 
deserves further attention as a possible GDNF therapeutic substitute.  
In parallel, progress in knowledge of the biochemistry of GFL receptors and the use of high-
throughput screening will hopefully led to discover GFRα specific agonists/antagonists and or to 
develop additional small molecules mimicking  the activity of the GFLs [3]. Today, XIB4035, a 
456.5 Da quinol binding to GFRα1, is the only available “ligand” of GFRα1 reported to induce RET 
autophosphorylation in Neuro-2A cells [82]. The molecule displaces GDNF from GFRα1 with an 
IC50 of 10 mM.  Very recently it was demonstrated not to be a true GFRα1 agonist, but rather to 
enhance the GFRα family receptor signaling [83]. In this study XIB4035 was administered topically 
and found effective to treat small fiber neuropathy in diabetic female rats.  
In chicken embryonic sympathetic neurons in vitro, GFRα1 and GFRα2, as well as the common 
signal transducing receptor RET, were all down-regulated by retinoic acid [84]. Interestingly, more 
recent work on mouse DRG neurons  showed that LE135, a retinoid acid receptor antagonist, 
produces pain through direct activation of TRP channels [85]. 
6. Conclusion 
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Although far from being ready for translational trials, animals studies, primarily in neuropathic 
pain, are strongly supportive of the possibility to develop effective new pain controlling strategies 
based on the intervention of GFLs in the modulation of nociceptive circuitry. As information has 
been added to a better comprehension of the neuronal circuitry involved in the growth factor 
modulation of glutamate release at the synapses between first- and second-order sensory neurons, 
and targeting GFRα receptors appear to be at hand, GFLs should deserve more attention in the 
immediate future as potential new drugs to target pathologic pain. 
7. Expert opinion 
Today there are no drugs that address ARTN, GDNF, or the GFRα isoforms in the clinical 
management of chronic pain. Here, I have presented the data in vivo that show the intervention of 
GFLs in the rodent somatosensory and visceral nociceptive pathways under normal conditions and 
after experimental inflammatory or neuropathic pain. In the  last years, many promising analgesic 
molecules in rodent pain models had limited or no translation into successful proof-of-concept 
clinical trials, to the point that several companies dropped their search efforts in finding novel 
analgesic drugs [86]. In line with this unfortunate tendency, there is at present only one phase 1 
study supporting the development of BG00010 for the treatment of neuropathic pain [74]. 
There is a general consensus that central sensitization at spinal and supraspinal levels is the key 
event in the development of pathological pain [1]. Two main lines of thought can then be followed 
to direct pain drug discovery strategies: the first (and most commonly followed) aims at producing 
compounds that can cross the BBB to directly interfere with central sensitization mechanisms, the 
second intends to hit the primary afferent neurons at periphery, in order to reduce or block central 
sensitization without the unwanted CNS side effects [87].  
Under this perspective ARNT, GDNF and related small molecule derivatives appear to be amenable 
to the development of new therapeutic strategies by primarily hitting neuropathic pain. Based on the 
previously discussed evidence of animal studies, and considering that GDNF has been demonstrated 
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to undergo both retrograde and anterograde transport in neurons [10, 31] it seems reasonable that, 
broadly-speaking, a GDNF-related therapy may be effective at both peripheral and central levels. In 
addition, as minimally invasive topical or systemic routes of administration other than the direct 
delivery into the central or the peripheral neurons have proved to be efficacious in animal models 
[4, 64, 81-83], it seems desirable that these routes are explored in clinical settings too. 
GDNF is not the only growth factor that intervenes in the modulation of the nociceptive input to the 
spinal cord, as BDNF is today generally acknowledged to act a pronociceptive factor [88]. 
Remarkably both factors are selectively stored in LGVs at central and, likely, peripheral terminals 
of nociceptors, BDNF being co-stored with the pronociceptive peptide substance P [14] and GDNF 
with the antinociceptive peptide SOM [11]. Noteworthy, SOM is upregulated by GDNF [13, 34, 35, 
56, 89], and the levels of both are reduced in patients suffering from chronic pain syndromes [69].  
An interesting option for developing new drugs is thus targeting the release of these pain-related 
messengers from LGVs, as their exocytosis is differentially regulated than that of the small synaptic 
vesicles storing the fast-acting transmitter glutamate that is responsible for acute pain. In 
nociceptive pathways, an ideal drug to target the release of endogenous GFLs from LGVs could act 
e.g. onto the phosphatidylinositol-3-phosphate [PtdIns(3)P] pool, which is sensitive to Ca
2+ 
modulation [90].  
An additional strategy would be to better exploit the efficacy of existing drugs that are currently 
used in different clinical settings and, therefore, would require a less-intensive research effort to be 
targeted to chronic pain treatment. One of these drugs could be the tricyclic antidepressant 
amitriptyline, as it was shown to decrease the release of BDNF [91], and, at the same time, increase 
that of GDNF at least in glia [92]. If one considers the picture emerged from a more precise 
dissection of the nociceptive circuitries in the substantia gelatinosa of the spinal cord (Figure2), 
amitriptyline has the potential to target at the same time a pro- (BDNF) and an antinociceptive 
(GDNF) factor at this very important relay station. Notably, a very recent study has shown that 
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systemic (intraperitoneal) amitriptyline reversed the effects of allodynia and hyperalgesia induced 
by chronic constriction injury (CCI) in mice [93], and case reports in the clinical literature indicate 
that high doses of topical amitriptyline are beneficial in the treatment of neuropathic pain although 
systemic adverse effects should be taken into account [94] . 
Retinoids, through their activation of retinoic acid receptors and retinoid X receptors, regulate 
diverse cellular processes, and pharmacological intervention in their actions was proved to be useful 
in the treatment of certain skin disorders and cancers. The aforementioned links between retinoic 
acid and chronic pain, albeit at present only established in vitro, will hopefully also deserve further 
attention in the future. 
The discussion of the failure of translational research in pain is beyond the purpose of this 
contribution, and the crucial limitations in animal pain models, their behavioral testing, and the 
experimental paradigms used to elicit pain were well outlined recently [95]. Still it remains 
confusing to many researchers that what is often tested in the laboratory is nociception rather than 
pain, and under this perspective an overcoming of the conventional reflex-based behavioral tests is 
mandatory with, at least, the complementary use of e.g. performance-based tests, facial mimics 
analysis, etc. 
Also the discussion on the opportunity to use spontaneous models of pain, such as pet animals that 
are widely diffused today and the subject on an increasing veterinary attention, is not a new one. 
Under this perspective, a further amelioration and refinement of the ex-vivo preparations will enable 
pain researchers to perform quicker and less expensive high-throughput screening experiments of 
drugs with potential antinociceptive effect. These antinociceptive drugs could be then tested for 
their potential analgesic effects in controlled veterinary trials on small animals suffering from 
inflammatory or neuropathic pain, and, finally, translated into human clinical trials.
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GFLs Species Type of experiment Type of pain Site/Mechanism of action  
ARTN Rat males (Sprague-Dawley)  
Mouse females 
(C57BL/6J) 
Intraplantar injection of 
CFA 
  
Mechanical hyperalgesia partly 
reversed by anti-ARTN antibodies 
[39] 
ARTN ARTN-OE and wild-type 
mice 
Intraplantar injection of 
ARTN 
Increased sensitivity to heat, cold, 
capsaicin and mustard oil in ARTN-
OE mice 
Transient thermal hyperalgesia 
in wild-type mice 
[40] 
ARTN Mouse Intraplantar injection of 
ARTN 
Cold hyperalgesia Activation of TRPM8-GFRα3  in 
sensory neurons [96] 
ARTN, 
GDNF, 
NRTN 
Mouse (C57BL/6J) Intraplantar injection of 
CFA 
Intraplantar injection of 
GFLs 
Thermal hyperalgesia Decrease of GDNF and NRTN 
expression after CFA, potentiation of 
TRPV1 response in isolated sensory 
neurons [41] 
GDNF Rat males (Sprague-Dawley) Intraplantar injection of 
CFA 
Thermal hyperalgesia blocked by 
GDNF 
Increased GDNF content and 
upregulation of TRPV1 in DRGs [45] 
ARTN, 
GDNF 
Rat males (Sprague-Dawley) Plantar incision Mechanical hyperalgesia 
Thermal hyperalgesia 
ARTN mRNA upregulation in skin and 
muscle; GDNF mRNA downregulation 
in skin, upregulation in muscle [46] 
GDNF Rat females (Wistar) Intradermal injection of 
GDNF  
Mechanical hyperalgesia IB4+ nociceptors [42] 
GDNF Rat males (Sprague-Dawley) Intradermal injection of 
GDNF 
Mechanical hyperalgesia IB4+ nociceptors [43] 
Activation of PKCε [44] 
Hyperalgesia blocked by DORs [97] 
GDNF Rat males (Sprague-Dawley) Intramuscular injection of 
GDNF 
Ergonomic muscular 
injury  
Acute/chronic muscle pain GFRα1 at IB4+ nociceptors 
[50] 
GDNF Rat males (Sprague-Dawley) Muscle lengthening 
contraction 
Mechanical hyperalgesia blocked 
by anti-GDNF antibodies 
COX2-dependent upregulation of GDNF 
mRNA [53] 
GDNF Rat males (Sprague-Dawley) Intramuscular injection of 
GDNF 
Mechanical hyperalgesia of Aδ-
fibres but not C-fibres  
ASIC-dependent, TRPV1-independent 
[51] 
GDNF Mouse males (C57BL/6J)  Muscle lengthening 
contraction 
Mechanical hyperalgesia [52] 
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Intramuscular injection of 
GDNF 
GDNF Rat males (Sprague-Dawley) Intraarticular injection of 
CFA 
Delayed thermal hyperalgesia  
decreased by anti-GNDF antibodies 
 [54] 
GDNF Rats Induction of bone cancer Mechanical and thermal 
hyperalgesia reduced by intrathecal 
lentivirus-mediated GDNF RNAi  
Downregulation of GDNF protein levels, 
Reduction of SP-IR 
Downregulation of the pERK⁄ERK [55] 
 
TABLE 1: Experimental data on the intervention of GFLs in inflammatory pain  
Abbreviations: ARTN = artemin; ASIC = acid-sensing ion channel; CFA = complete Freund’s adjuvant; COX2 = Cyclooygenase 2; DORs = δ-opioid receptors; 
DRGs = dorsal root ganglia; ERK = extracellular-signal-regulated kinase; GFL = GDNF family of ligands; GFRα: GDNF family receptor α; GNDF = glial-
derived neurotrophic factor;  IB4 = isolectin B4; IR = immunoreactivity; NRTN = neurturin; OE = overexpressing; pERK = phosphorylated form of extracellular-
signal-regulated kinase; PKCε = protein kinase Cε; RNAi = RNA interference; SP = substance P; TRPV1 = transient receptor potential channel vanilloid type 1 
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GFLs Species Type of experiment Type of pain Site/Mechanism of action of GLFs  
ARTN Rats males (Sprague-
Dawley) 
SNL Mechanical and thermal 
hypersensitivity blocked by ARTN 
(subcutaneous) 
Reversal of the increase of GFRα3 and 
of the loss of IB4+ nociceptors in DRGs 
and reduction of SNL-potentiated 
capsaicin CGRP release [4] 
ARTN Rat males (Sprague-Dawley) 
Mouse females 
(C57BL/6J) 
PSL Mechanical hyperalgesia not 
reversed by anti-ARTN antibodies 
[39] 
GDNF Rats females 
(Sprague-Dawley) 
Partial transection of 
sciatic nerve branches 
Neuropathic pain and allodynia 
blocked by GDNF (continuous – 
intrathecal or peripheral within a 
chitosan matrix) 
Increased expression/secretion of SOM 
from DRG neurons [56] 
GDNF Rats PSL or SNL Neuropathic pain blocked by GDNF 
(intrathecal) 
Reversal of the injury-induced plasticity 
of several sodium channel subunits [57] 
GDNF Rat males (Sprague-Dawley) CCI 
SNL 
Mechanical and thermal 
hypersensitivity blocked by GDNF 
(intrathecal) 
Reduction of GDNF content and 
percentages of RET-IR neurons in DRGs 
[58] 
GDNF Rats CCI Reduction of mechanical allodynia 
by GDNF  
Effect of GDNF abolished by NCAM 
antisense oligodeoxynucleotides or C3d, 
an NCAM-mimetic peptide [98]  
GDNF Rat males (Sprague-Dawley) SNL Development of thermal and tactile 
hypersensitivity prevented by 
GDNF (intrathecal)  
Attenuation of reduction of IB4+/  
increase of ATF-3/galanin in DRGs [59] 
GDNF  Rats (Wistar) SNL Neuropathic pain mechanical 
allodynia and thermal hyperalgesia 
attenuated by lentiviral-mediated 
GDNF transfer (intraspinal) 
Reversal of IB4+ downregulation and  
ATF-3 upregulation in DRGs [61] 
GDNF Rat SNL Mechanical hyperalgesia and 
allodynia attenuated by lentivector 
transduced MSCs (intraDRGs) 
MSC secretion of GDNF [63] 
GDNF Rats males (Sprague-
Dawley) 
CCI Mechanical allodynia and thermal 
hyperalgesia attenuated by 
adenoviral-mediated GDNF transfer  
(intramuscular) 
Protective action associated with anti-
inflammation and prohibition of 
microglia activation [64] 
GDNF Rats males (Sprague-
Dawley) 
CCI Allodynia and thermal hyperalgesia 
blocked by injection of GDNF in 
Enhancement of descending 
noradrenergic inhibition [65] 
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locus coeruleus 
GDNF Rats males (Sprague-
Dawley) 
CCI and  
electroacupuncture 
analgesia 
Heat hyperalgesia   Exacerbation of hyperalgesia [89] or 
block of analgesia by antisense GFRα1 
oligodeoxynucleotides [99] 
GDNF Rat PSL Tactile allodynia reduced by 
gamma knife (GK) irradiation 
Increase of GDNF and Iba-1 protein, a 
macrophage marker, in peripheral nerves 
[100] 
GDNF Mouse males C57BL/6J CCI Thermal hyperalgesia attenuated by 
GDNF (intrathecal) 
GDNF counteracted the downregulation 
of E-cadherin/p120ctn in dorsal horn 
[60] 
GDNF Mouse males C57BL/6J  SNL Mechanical hyperalgesia partly 
reversed by lentiviral vector-
mediated GDNF overexpression 
(intraspinal or intraDRGs) 
[62] 
GDNF Y1472F-KI and wild type 
C57BL/6J mice 
Induced herpetic neuralgia  Spontaneous pain and allodynia  Decrease in GDNF-IR fibers  in spinal 
cord, reduction of NMDA-induced 
current in spinal cord slices by GDNF 
[66] 
 
TABLE 1: Experimental data on the intervention of GFLs in neuropathic pain  
Abbreviations: ARTN = artemin; ATF-3 = activating transcription factor 3; CCI = Chronic constriction injury of sciatic nerve; CGRP = calcitonin gene-related 
peptide; DRGs = dorsal root ganglia; GFL = GDNF family of ligands; GNDF = glial-derived neurotrophic factor;  IB4 = isolectin B4; IR = immunoreactive; 
NCAM= neural cell adhesion molecule; MSCs = mesenchymal stem cells; PSL = partial ligation of sciatic nerve; SOM = somatostatin; RET = receptor tyrosine 
kinase (RTK) rearranged during transfection; SNL = spinal nerve ligation.  
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Figure 1 
Simplified scheme of the main nociceptive pathways in mammals.  
Nociceptive pathways consist of polyneuronal chains of neurons that originate from a 
pseudounipolar primary sensory neurons neuron (nociceptor) in the peripheral nervous system. 
Primary sensory neurons are localized in CNSGs, DRGs or TG. Nociceptive somatic inputs from all 
the parts of the body except the head are transferred to second-order spino-thalamic projection 
neurons in the dorsal horn of the spinal cord. These neurons give rise to the spino-thalamic tracts 
that reach the third-order neurons in VPLNu. Nociceptive somatic inputs from the head are relayed 
to the SNuT and then, along the trigemino-thalamic fibers, to the VPMNu. Nociceptive visceral 
afferents mainly derive from CNSGs associated to the vagus and glossopharyngeal nerves and are 
the relayed to the NuTS, the PBNu, and, finally the VPLNu(p). There is a small contingent of 
visceral afferents also in DRGs (less than 5%). From the thalamus, the nociceptive input is finally 
transferred to the sensory cortex where it gives rise to the sensation of pain. There are indirect 
connections (dashed lines with arrows) between the somatic and visceral pathways, which are the 
anatomical basis for the so called referred visceral pain, a condition in which visceral pain is 
perceived as originating from somatic structures. For simplicity the descending inhibitory pathways 
are not represented, as well as the connections with the limbic system that is responsible for the 
emotional and affective components of pain.  
Abbreviations: CNS = central nervous system; CNSGs = cranial nerve sensory ganglia; DRGs = 
dorsal root ganglia; NuTS = nucleus tractus solitarii; PBNu = parabrachial nucleus; PNS = 
peripheral nervous system; STN = spino-thalamic neuron; SNuT = spinal nucleus of the trigeminal 
nerve; VPLNu = ventro-postero lateral nucleus of the thalamus; VPLNu(p) = ventro-postero lateral 
nucleus of the thalamus – parvocellular part; VPMNu = ventro-postero medial nucleus of the 
thalamus. Roman numerals indicate the order of the neurons along their polysynaptic chain. 
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Figure 2 
Sites of potential GDNF modulation of nociceptive input in substantia gelatinosa (lamina II) of the 
spinal dorsal horn. 
GDNF is released from LGVs in peptidergic (CGRP+/SST28+) type Ib glomeruli made by Aδ/C 
fibers in substantia gelatinosa. Once released, GDNF can negatively modulate glutamate release by 
acting on GFRα1-IR dendrites at three different types of glomeruli. Under conditions of nociceptive 
physiological pain GDNF counteracts the positive modulatory action of BDNF by acting on the 
subpopulation of Aδ/C fibers expressing BDNF which are engaged in peptidergic (CGRP+/SP+) 
type Ib glomeruli displaying GFRα1-IR at their peripheral dendrites. GDNF can also negatively 
modulate the glutamate release from non-peptidergic, IB4+ C fibers at type Ia glomeruli. These 
fibers have been shown to be the preferential target for the anti-nociceptive action of GDNF in 
animal models of neuropathic pain (see text). When central sensitization occurs, BDNF recruits 
non-nociceptive Aβ fibers at type II glomeruli. Since at least some of these fibers express the 
GFRα1/RET complex they can be an additional potential target for the antinociceptive effects of 
GDNF. For details see [11, 15]. 
Abbreviations: BDNF = brain-derived neurotrophic factor; CGRP = calcitonin genre-related 
peptide; SP = substance P; SST28 = 28 amino acid somatostatin; GFRα1 = GDNF family receptor 
α1; IB4 = isolectin B4; RET = receptor tyrosine kinase (RTK) rearranged during transfection; TrkB 
= tyrosine kinase receptor B 
